ZYVERSA THERAPEUTICS, INC. Stock-Based Compensation
ZYVERSA THERAPEUTICS, INC. (ZVSA) reported Stock-Based Compensation of $55.87 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-05-13
- ZYVERSA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $55.87K, a 63.69% decline year-over-year.
- ZYVERSA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $17.35K, a 89.20% decline year-over-year.
- ZYVERSA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $73.99K, a 53.95% decline year-over-year.
- ZYVERSA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-06-30 was -$22.40K, a 113.94% decline year-over-year.
- ZYVERSA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $222.83K, a 68.42% decline from fiscal 2024.
- ZYVERSA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $705.57K, a 40.86% decline from fiscal 2023.
- ZYVERSA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $1.19M.
| Period end | Share-based Payment Arrangement, Noncash Expense 1 month | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 3 month as first filed | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 11 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2026-03-31 | $55.87K 10-Q · filed 2026-05-13 | $73.22K derived: sum of 2 quarters · filed 2026-05-13 | $147.21K derived: sum of 3 quarters · filed 2026-05-13 | $124.81K derived: sum of 4 quarters · filed 2026-05-13 | |||
| 2025-12-31 | $17.35K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $91.34K derived: sum of 2 quarters · filed 2026-03-31 | $68.94K derived: sum of 3 quarters · filed 2026-03-31 | $222.83K 10-K · filed 2026-03-31 | |||
| 2025-09-30 | $73.99K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | $51.59K derived: sum of 2 quarters · filed 2025-11-19 | $205.48K 10-Q · filed 2025-11-19 | $366.14K derived: sum of 4 quarters · filed 2026-05-13 | |||
| 2025-06-30 | -$22.40K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $131.49K 10-Q · filed 2025-08-13 | $292.15K derived: sum of 3 quarters · filed 2026-05-13 | $452.82K derived: sum of 4 quarters · filed 2026-05-13 | |||
| 2025-03-31 | $153.89K 10-Q · filed 2026-05-13 | $72.29K 10-Q · filed 2025-05-12 | $314.56K derived: sum of 2 quarters · filed 2026-05-13 | $475.22K derived: sum of 3 quarters · filed 2026-05-13 | $635.88K derived: sum of 4 quarters · filed 2026-05-13 | ||
| 2024-12-31 | $160.66K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $321.33K derived: sum of 2 quarters · filed 2026-03-31 | $481.99K derived: sum of 3 quarters · filed 2026-03-31 | $705.57K 10-K · filed 2026-03-31 | |||
| 2024-09-30 | $160.66K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | $321.33K derived: sum of 2 quarters · filed 2025-11-19 | $544.90K 10-Q · filed 2025-11-19 | $841.62K derived: sum of 4 quarters · filed 2025-11-19 | |||
| 2024-06-30 | $160.66K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $384.24K 10-Q · filed 2025-08-13 | $680.95K derived: sum of 3 quarters · filed 2025-08-13 | $924.00K derived: sum of 4 quarters · filed 2025-08-13 | |||
| 2024-03-31 | $223.57K 10-Q · filed 2025-05-12 | $520.29K derived: sum of 2 quarters · filed 2025-05-12 | $763.33K derived: sum of 3 quarters · filed 2025-05-12 | $1.13M derived: sum of 4 quarters · filed 2025-05-12 | |||
| 2023-12-31 | $296.71K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $539.76K derived: sum of 2 quarters · filed 2025-03-27 | $905.50K derived: sum of 3 quarters · filed 2025-03-27 | $1.19M 10-K · filed 2025-03-27 | |||
| 2023-09-30 | $243.04K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $608.79K derived: sum of 2 quarters · filed 2024-11-14 | $896.25K 10-Q · filed 2024-11-14 | ||||
| 2023-06-30 | $365.74K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $653.20K 10-Q · filed 2024-08-09 | |||||
| 2023-03-31 | $287.46K 10-Q · filed 2024-05-15 | ||||||
| 2022-12-31 | $56.33K 10-K · filed 2024-03-25 | ||||||
| 2022-12-12 | $3.52M 10-K · filed 2024-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |